Showing 15 posts of 90 posts found.

Boehringer blood cancer drug scores in Phase II

July 9, 2014
Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib

Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …

Amgen image

FDA breakthrough for Amgen

July 2, 2014
Research and Development, Sales and Marketing Amgen, BiTE antibody blinatumomab, FDA, all, leukaemia

Amgen has taken a major step down the road to getting its investigational cancer drug blinatumomab onto the market after …

Janssen image

FDA extends licence for Janssen’s Imbruvica

February 13, 2014
Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia

Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …

iclusig image

EMA in new Iclusig probe

December 9, 2013
Sales and Marketing Ariad, EMA, iclusig, leukaemia

Europe’s medicines regulator has begun a new review of Ariad Pharmaceuticals’ leukaemia drug Iclusig, looking in particular at the risk …

Iclusig image

Ariad cancer drug pulled amid safety fears

November 1, 2013
Sales and Marketing Ariad, FDA, iclusig, leukaemia

Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …

Roche image

New Roche leukaemia drug beats rival

July 24, 2013
Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab

Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …

Roche leukaemia drug granted speedy US review

July 3, 2013
Research and Development, Sales and Marketing CLL, FDA, Roche, leukaemia, obinutuzumab

Roche’s investigational leukaemia drug could be available for US patients by the end of the year as the FDA looks …

Ariad expands in Europe

February 22, 2013
Sales and Marketing Ariad, leukaemia, leukemia

The new European boss of Ariad Pharmaceuticals has sketched out the US firm’s plans for its next-generation leukaemia drug, which …

Blood cancer charity to kick-start clinical trials

May 19, 2011
Research and Development Cancer, blood cancer, clinical trials, leukaemia

A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …

Leukaemia drug fast-tracked by NICE

January 6, 2011
Sales and Marketing Bendamustine, Levact, NICE, Napp, chronic lymphocytic leukaemia, leukaemia

A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …

Quarter of all cancers found at late stage

November 15, 2010
Cancer, England, NCIN, NHS, National Cancer Intelligence Network, brain cancer, cancer diagnosis, leukaemia

Nearly a quarter of all cancer diagnoses in England came after a patient had been admitted to hospital for emergency …

Tasigna more effective than Glivec, says Novartis

June 21, 2010
Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia

Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …

Antisoma stages comeback with promising cancer drugs

May 20, 2010
Research and Development AML, Antisoma, chemotherapy, leukaemia

UK biotech Antisoma is looking to put previous late-stage trial failures behind it by focusing on two new cancer drugs. …

GSK’s Arzerra conditionally approved in Europe

April 20, 2010
Research and Development, Sales and Marketing Arzerra, GSK, leukaemia

GlaxoSmithKline’s orphan cancer treatment Arzerra has been given conditional marketing authorisation in the European Union. Arzerra (ofatumumab) can be used …

Cancer Research UK and Merck KGaA to co-develop leukaemia candidate

January 4, 2010
Research and Development Merck Serono, leukaemia, oncology

Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialisation arm, are to undertake a phase I …

Latest content